Journey Medical FY2025 revenue $61.9M (+10% YoY); net loss narrows to $11.4M

Journey Medical Corp

Emrosi launch contributed $14.7M net revenue; ~53,000 prescriptions filled in FY2025.
Gross margin improved to 66.2% from 62.8%, driven by higher-margin Emrosi and Qbrexza.
Adjusted EBITDA positive $2.9M ($0.12 per diluted share) vs $0.8M in prior year.
SG&A rose 10% to $44.4M due to Emrosi commercialization costs.
Accutane revenue declined $6.5M amid competitive pressures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.